Literature DB >> 12484571

Neuropathological changes in a mouse model of progressive myoclonus epilepsy: cystatin B deficiency and Unverricht-Lundborg disease.

Patrick Shannon1, Len A Pennacchio, Megan K Houseweart, Berge A Minassian, Richard M Myers.   

Abstract

Progressive myoclonus epilepsy of the Unverricht-Lundborg type (EPM1) is a recessively inherited neurodegenerative disease caused by loss-of-function mutations in the gene encoding cystatin B, a cysteine protease inhibitor. Mice with disruptions in this gene display myoclonic seizures, progressive ataxia, and cerebellar pathology closely paralleling EPMI in humans. To provide further insight into our understanding of EPM1, we report pathological findings in brains from cystatin B-deficient mice. In addition to confirming the loss of cerebellar granular cell neurons by apoptosis, we identified additional neuronal apoptosis in young mutant mice (3-4 months old) within the hippocampal formation and entorhinal cortex. In older mutant mice (16-18 months old), there was also gliosis most marked in the presubiculum and parasubiculum of the hippocampal formation, as well as the entorhinal cortex, neocortex, and striatum. Furthermore, widespread white matter gliosis was also noted, which may be a secondary phenomenon. Within the cerebral cortex, cellular atrophy was a prominent finding in the superficial neurons of the prosubiculum. Finally, we show that mutant mice in either a "seizure-prone" or "seizure-resistant" genetic background display similar neuropathological changes. These findings indicate that neuronal atrophy is an important consequence of cystatin-B deficiency independent of seizure events, suggesting a physiological role for this protein in the maintenance of normal neuronal structure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12484571     DOI: 10.1093/jnen/61.12.1085

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  22 in total

Review 1.  Progressive myoclonic epilepsies: review of clinical, molecular and therapeutic aspects.

Authors:  Luis Felipe Mendonça de Siqueira
Journal:  J Neurol       Date:  2010-07-01       Impact factor: 4.849

2.  Role of cystatin C in neuroprotection and its therapeutic implications.

Authors:  Luciano D'Adamio
Journal:  Am J Pathol       Date:  2010-09-23       Impact factor: 4.307

Review 3.  Cystatin superfamily.

Authors:  Josiah Ochieng; Gautam Chaudhuri
Journal:  J Health Care Poor Underserved       Date:  2010-02

4.  Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits.

Authors:  Dun-Sheng Yang; Philip Stavrides; Panaiyur S Mohan; Susmita Kaushik; Asok Kumar; Masuo Ohno; Stephen D Schmidt; Daniel Wesson; Urmi Bandyopadhyay; Ying Jiang; Monika Pawlik; Corrinne M Peterhoff; Austin J Yang; Donald A Wilson; Peter St George-Hyslop; David Westaway; Paul M Mathews; Efrat Levy; Ana M Cuervo; Ralph A Nixon
Journal:  Brain       Date:  2011-01       Impact factor: 13.501

5.  Identification of a new JME gene implicates reduced apoptotic neuronal death as a mechanism of epileptogenesis.

Authors:  Robyn Wallace
Journal:  Epilepsy Curr       Date:  2005 Jan-Feb       Impact factor: 7.500

6.  A new, progressive myoclonic epilepsy: is it a chronicle of the noncanonical or a failure to REST?

Authors:  Martin Gallagher
Journal:  Epilepsy Curr       Date:  2009 May-Jun       Impact factor: 7.500

Review 7.  The best evidence for progressive myoclonic epilepsy: A pathway to precision therapy.

Authors:  Alessandro Orsini; Angelo Valetto; Veronica Bertini; Mariagrazia Esposito; Niccolò Carli; Berge A Minassian; Alice Bonuccelli; Diego Peroni; Roberto Michelucci; Pasquale Striano
Journal:  Seizure       Date:  2019-08-23       Impact factor: 3.184

8.  Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes.

Authors:  B Bindukumar; S D Mahajan; J L Reynolds; Z Hu; D E Sykes; R Aalinkeel; S A Schwartz
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

Review 9.  Molecular background of progressive myoclonus epilepsy.

Authors:  Anna-Elina Lehesjoki
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

10.  Epileptogenic potential of mefloquine chemoprophylaxis: a pathogenic hypothesis.

Authors:  Remington L Nevin
Journal:  Malar J       Date:  2009-08-05       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.